Free Trial

Y-mAbs Therapeutics (YMAB) Competitors

Y-mAbs Therapeutics logo
$8.61 0.00 (0.00%)
As of 09/16/2025

YMAB vs. PAHC, SDGR, AUPH, AVDL, JANX, EVO, RCUS, STOK, LENZ, and SNDX

Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Phibro Animal Health (PAHC), Schrodinger (SDGR), Aurinia Pharmaceuticals (AUPH), Avadel Pharmaceuticals (AVDL), Janux Therapeutics (JANX), Evotec (EVO), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.

Y-mAbs Therapeutics vs. Its Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Y-mAbs Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

70.9% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 19.7% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Phibro Animal Health has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs Therapeutics$87.68M4.46-$29.67M-$0.50-17.22
Phibro Animal Health$1.30B1.14$48.26M$1.1831.00

In the previous week, Phibro Animal Health had 19 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 20 mentions for Phibro Animal Health and 1 mentions for Y-mAbs Therapeutics. Phibro Animal Health's average media sentiment score of 0.64 beat Y-mAbs Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Y-mAbs Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Phibro Animal Health
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Phibro Animal Health has a net margin of 3.73% compared to Y-mAbs Therapeutics' net margin of -26.03%. Phibro Animal Health's return on equity of 32.14% beat Y-mAbs Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Y-mAbs Therapeutics-26.03% -24.60% -18.89%
Phibro Animal Health 3.73%32.14%6.89%

Y-mAbs Therapeutics presently has a consensus price target of $9.62, indicating a potential upside of 11.76%. Phibro Animal Health has a consensus price target of $28.40, indicating a potential downside of 22.36%. Given Y-mAbs Therapeutics' higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Y-mAbs Therapeutics
2 Sell rating(s)
8 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Phibro Animal Health
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.13

Summary

Phibro Animal Health beats Y-mAbs Therapeutics on 15 of the 17 factors compared between the two stocks.

Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YMAB vs. The Competition

MetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$391.24M$3.36B$6.05B$10.30B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-17.2222.0885.3127.10
Price / Sales4.46478.69601.46133.24
Price / CashN/A44.9825.7730.18
Price / Book4.2010.3812.676.69
Net Income-$29.67M-$52.47M$3.32B$276.55M
7 Day PerformanceN/A0.18%-0.06%-0.40%
1 Month Performance0.23%13.95%8.73%6.53%
1 Year Performance-40.78%20.83%78.85%41.04%

Y-mAbs Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
YMAB
Y-mAbs Therapeutics
1.2698 of 5 stars
$8.61
flat
$9.62
+11.8%
N/A$391.24M$87.68M-17.22150News Coverage
PAHC
Phibro Animal Health
4.366 of 5 stars
$37.79
-1.4%
$28.40
-24.8%
+55.7%$1.55B$1.30B32.032,475Analyst Revision
SDGR
Schrodinger
2.9074 of 5 stars
$21.29
+3.4%
$26.57
+24.8%
+11.5%$1.52B$207.54M-8.58790
AUPH
Aurinia Pharmaceuticals
3.487 of 5 stars
$11.32
-0.3%
$13.00
+14.8%
+56.8%$1.49B$235.13M26.33300Positive News
AVDL
Avadel Pharmaceuticals
2.8222 of 5 stars
$14.53
-3.2%
$20.86
+43.5%
+8.2%$1.46B$169.12M-484.3370
JANX
Janux Therapeutics
2.5608 of 5 stars
$22.76
-5.2%
$78.31
+244.1%
-46.9%$1.44B$10.59M-12.6430
EVO
Evotec
2.1463 of 5 stars
$3.99
-0.5%
$5.40
+35.3%
+25.8%$1.42B$862.40M0.004,827
RCUS
Arcus Biosciences
1.9677 of 5 stars
$14.54
+8.9%
$21.14
+45.4%
-9.4%$1.42B$258M-4.59500News Coverage
Analyst Forecast
Gap Up
High Trading Volume
STOK
Stoke Therapeutics
2.9699 of 5 stars
$26.81
+4.9%
$25.57
-4.6%
+156.3%$1.40B$36.56M31.54100Analyst Forecast
Insider Trade
LENZ
LENZ Therapeutics
1.7404 of 5 stars
$46.11
-5.4%
$49.60
+7.6%
+56.3%$1.39BN/A-24.27110Analyst Forecast
SNDX
Syndax Pharmaceuticals
3.6148 of 5 stars
$16.40
+5.1%
$39.22
+139.2%
-20.5%$1.34B$23.68M-4.22110

Related Companies and Tools


This page (NASDAQ:YMAB) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners